Vaccinex, Inc.
(NASDAQ : VCNX)

( )
VCNX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.36%352.430.0%$5529.05m
BNTXBioNTech SE -2.97%351.740.0%$1554.09m
NVAXNovavax, Inc. 7.56%208.6378.2%$1149.83m
AMGNAmgen, Inc. -2.26%198.881.4%$591.30m
LGVNLongeveron Inc. 0.04%26.260.0%$511.78m
GILDGilead Sciences, Inc. -2.44%68.931.0%$497.91m
REGNRegeneron Pharmaceuticals, Inc. -2.73%636.532.7%$490.45m
VRTXVertex Pharmaceuticals, Inc. -1.67%186.941.9%$375.32m
SNSSSunesis Pharmaceuticals, Inc. 0.88%4.610.7%$322.26m
ILMNIllumina, Inc. -1.48%365.333.3%$311.28m
OCGNOcugen, Inc. -1.40%6.340.0%$293.70m
BIIBBiogen, Inc. -0.16%235.741.8%$289.61m
EXASEXACT Sciences Corp. -1.39%85.3718.0%$167.68m
INCYIncyte Corp. -3.77%67.722.4%$165.57m
BMRNBioMarin Pharmaceutical, Inc. -1.27%86.294.2%$144.64m

Company Profile

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington’s disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in April 2001 and is headquartered in Rochester, NY.